Two-once-daily fixed-dose NRTI combinations for HIV
- PMID: 15767973
Item in Clipboard
Two-once-daily fixed-dose NRTI combinations for HIV
Med Lett Drugs Ther.
.
Abstract
Abacavir/lamivudine (Epzicom) and emtricitabine/tenofovir (Truvada), two new once-daily fixed-dose NRTI combinations, have been approved for use in antiretroviral regimens to treat HIV infection. Epzicom appears to be as effective as its components taken separately and, in one study, Truvada was at least as effective as zidovudine/lamivudine (Combivir). Use of once-daily fixed-dose combinations means less flexibility in dosing, and some patients with hepatic or renal impairment will not be able to take them.
Similar articles
-
Switching Combivir to Truvada keeps HIV undetectable, improves blood fats, fails to improve limb fat.Proj Inf Perspect. 2008 Dec;(47):8. Proj Inf Perspect. 2008. PMID: 19227559 No abstract available.
-
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.Pharmacotherapy. 2008 Mar;28(3):314-22. doi: 10.1592/phco.28.3.314. Pharmacotherapy. 2008. PMID: 18294111 Clinical Trial.
-
A truvada hypersensitivity reaction simulating abacavir hypersensitivity.AIDS. 2007 Oct 18;21(16):2252-3. doi: 10.1097/QAD.0b013e3282f08b84. AIDS. 2007. PMID: 18090057 No abstract available.
-
Emtricitabine/tenofovir (Truvada) for HIV prophylaxis.Am Fam Physician. 2013 Oct 15;88(8):535-40. Am Fam Physician. 2013. PMID: 24364575 Review. No abstract available.
-
Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.Expert Rev Anti Infect Ther. 2006 Aug;4(4):523-35. doi: 10.1586/14787210.4.4.523. Expert Rev Anti Infect Ther. 2006. PMID: 17009933 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
